Literature DB >> 5789809

Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed.

W H Aellig, B Berde.   

Abstract

1. Six ergot alkaloids were tested for their effect on vascular resistance and for alpha-adrenergic blocking activity on the innervated perfused hind limb of the dog. The results were compared with those obtained earlier for three compounds of the ergotamine group.2. Ergostine, dihydroergostine, 1-methylergostine and dihydroergocristine resembled ergotamine, dihydroergotamine and 1-methylergotamine in eliciting vasoconstriction at low vascular resistance and vasodilatation at high vascular resistance. The changeover occurred at the following "inversion points": ergostine and dihydroergostine as with ergotamine and dihydroergotamine at about 4 R.U.; 1-methylergostine as with 1-methylergotamine at about 2.3 R.U.; dihydroergocristine at about 1.9 R.U. [1 R.U. = 1 resistance unit = 1 mm Hg/ml. per min.]3. 1-methyldihydroergocristine consistently elicited vasodilatation (for initial vascular resistances down to 1.3 R.U.) and 5'-methylergoalanine always caused vasoconstriction (for initial values up to 5.8 R.U.).4. Ergostine and 5'-methylergoalanine had the most powerful vasoconstrictor effect, which was of the same order of magnitude as that of ergotamine. Dihydroergostine, like dihydroergotamine, was considerably less active. Both 1-methylergostine and 1-methylergotamine elicited only weak vasoconstriction. Moreover, when the initial vascular resistance exceeded the critical inversion value, they elicited only weak vasodilatation. Dihydroergocristine and 1-methyldihydroergocristine had the least effect on vascular resistance.5. The increase in vascular resistance by noradrenaline was inhibited in a dose-dependent manner by all the ergot alkaloids investigated. Ergostine, 5'-methylergoalanine and ergotamine had the greatest alpha-adrenergic blocking activity and 1-methylergostine, 1-methyldihydroergocristine and 1-methylergotamine the weakest. The activity of dihydroergostine, dihydroergocristine and dihydroergotamine fell between these two extremes.6. No correlation was found between the qualitative effect of these ergot alkaloids on vascular resistance (inversion point) and (a) their quantitative effect on this parameter or (b) their alpha-adrenergic blocking activity. Determination of the inversion point thus provides additional pharmacological information on the vasoactive properties of the ergot alkaloids.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5789809      PMCID: PMC1703604          DOI: 10.1111/j.1476-5381.1969.tb08011.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  3 in total

1.  Investigations on the hypotensive effect of the hydrogenated ergot alkaloids.

Authors:  H KONZETT; E ROTHLIN
Journal:  Br J Pharmacol Chemother       Date:  1953-06

2.  [Not Available].

Authors:  E ROTHLIN; A CERLETTI
Journal:  Helv Physiol Pharmacol Acta       Date:  1949-11

3.  [Peripheral circulatory effects of ergotamine, dihyroergotamine and 1-methylergotamine on the innevated, perfused hindlimb of the o].

Authors:  W H Aellig
Journal:  Helv Physiol Pharmacol Acta       Date:  1967
  3 in total
  10 in total

1.  Effect of dihydroergocristine infusion on tolbutamide-induced insulin secretion in man.

Authors:  F Caviezel; M Poli; A M Girardi; G Pozza
Journal:  Experientia       Date:  1979-10-15

2.  Investigation of the venoconstrictor effect of 8' hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Pharmacological actions of the main metabolites of dihydroergotamine.

Authors:  E Müller-Schweinitzer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  The effects of nitroglycerin on exercise-induced regional myocardial contractile dysfunction are not diminished by pretreatment with dihydroergotamine.

Authors:  W Schneider; G Krumpl; N Mayer; G Raberger
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

Review 5.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Dihydroergotamine increases the bioavailability of orally administered etilefrine.

Authors:  J H Hengstmann; R Hengstmann; S Schwonzen; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Actions of co-dergocrine mesylate and its components at vascular smooth muscle.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-02       Impact factor: 3.000

8.  Effects of dihydroergotamine (DHE) on blood flow and metabolism in the underperfused myocardium in anaesthetized dogs.

Authors:  R Seitelberger; W Schütz; G Raberger
Journal:  Basic Res Cardiol       Date:  1984 Jul-Aug       Impact factor: 17.165

9.  Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects.

Authors:  P A Wyss; J Rosenthaler; E Nüesch; W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Arterial Responses to Acute Low-Level Ergot Exposure in Hereford Cows.

Authors:  Vanessa Elizabeth Cowan; Alex Neumann; John McKinnon; Barry Raymond Blakley; Taylor Jayne Grusie; Jaswant Singh
Journal:  Front Vet Sci       Date:  2018-10-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.